Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor-Reference-Cited by-同舟云学术

Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor

Published:2014-02 Issue: Volume:77 Page:334-341
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Bonifácio M.J.,Sutcliffe J.S.,Torrão L.,Wright L.C.,Soares-da-Silva P.

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference35 articles.

1. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592;Acquas;J. Neurochem.,1992

2. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor;Almeida;Clin. Pharmacokinet.,2013

3. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease;Bonifácio;CNS Drug Rev.,2007

4. Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release;Chen;J. Neurochem.,2006

5. Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum;Chen;J. Neurosci.,2001

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catechol-O-methyltransferase (COMT);Metalloenzymes;2024

2. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach;Expert Review of Neurotherapeutics;2023-01-02

3. Adverse event profiles of adjuvant treatment with opicapone in Parkinson’s disease: A systematic review and meta-analysis;Frontiers in Pharmacology;2022-11-24

4. Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease;NeuroPsychopharmacotherapy;2022

5. Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping;Pharmacology Research & Perspectives;2021-12-22